How a Venomous Desert Lizard Helped Lead Scientists to Ozempic

The unlikely journey starts with the "Gila monster".

One of the hottest classes of drugs in the world owes part of its origin story to a weird desert lizard with a venomous bite and a prehistoric-looking face.

Meet the Gila monster. Hidden in its venom is a molecule that helped crack a problem scientists had struggled with for decades: how to control blood sugar and appetite in a way the human body could actually sustain. That line of research helped launch the GLP-1 drug revolution and, eventually, cleared the way for treatments such as Ozempic and Wegovy.

Built For Long Fasts

The Gila monster is one of the few venomous lizards on Earth. It lives mostly underground, eats only occasionally, and delivers venom through grooved teeth. Its bite can cause severe pain, swelling, and nausea in humans, though they rarely if ever attack humans.

Researchers first became interested in the animal because of its unusual feeding pattern: it could go long stretches without food, then consume an enormous meal in one sitting. That prompted a simple but important question: how did its body keep blood sugar under control under such extreme conditions?

If you don’t eat for long periods, blood sugar tends to drop. If you then eat a huge meal, it spikes sharply. Managing those swings requires very tight hormonal control, and even then it’s not perfect. That suggests it has unusually effective biochemical tools for regulating glucose. For scientists, that’s a big deal because it’s exactly the type of ability that can lead to better drugs.

In the 1980s and 1990s, scientists studying the lizard’s venom found a peptide (a small protein fragment) called exendin-4. It looked a lot like a human hormone called GLP-1—glucagon-like peptide-1. This hormone helps the body release insulin, slows digestion, and reduces appetite.

That made exendin-4 immediately interesting. Scientists already knew GLP-1 could be useful in treating diabetes. The problem was that natural human GLP-1 breaks down very quickly in the body. It does not stick around long enough to make a practical medicine.

Exendin-4 offered a way around that problem. It behaved like GLP-1, but lasted much longer.

×

Get smarter every day...

Stay ahead with ZME Science and subscribe.

Daily Newsletter
The science you need to know, every weekday.

Weekly Newsletter
A week in science, all in one place. Sends every Sunday.
No spam, ever. Unsubscribe anytime. Review our Privacy Policy.

Thank you! One more thing...

Please check your inbox and confirm your subscription.

RelatedPosts

Obese people enjoy their food more — and this could be key to understanding obesity
Your Gut Bacteria Are Eating More Than We Thought and That’s a Good Thing
Chicken korma shows why we like the food we like
Bee venom could be used to detect explosives and pesticides

Initially Too Strange

Endocrinologist John Eng played a central role in turning that insight into a drug lead. Revisiting earlier work on Gila monster venom, he recognized that one of its compounds might form the basis of a treatment for type 2 diabetes.

Eng identified exendin-4 and published the finding in 1992. But drug companies were skeptical. Peptide drugs had a reputation for being hard to develop, expensive to make, and inconvenient for patients, who usually had to inject them.

Eng kept going anyway.

According to Danish researcher Jens Juul Holst, “He was extremely frustrated. Nobody was interested in his work. None of the important people. It was too strange for people to accept.”

Eventually, Amylin Pharmaceuticals licensed the technology and developed a synthetic version of exendin-4 called exenatide. In 2005, the U.S. Food and Drug Administration approved it as Byetta for type 2 diabetes.

That moment changed the field. Byetta was an intermediate step to Ozempic. It wasn’t the polished, once-weekly treatment many people know today. But it proved that activating the GLP-1 pathway could work as a real therapy.

The Gila monster, in other words, provided one of the first workable templates for a longer-lasting GLP-1-style drug.

From Venom to Blockbuster Drugs

The lizard did not directly give the world semaglutide. But it did offer something essential: early proof that a longer-lasting GLP-1-like drug could work. Lizards are obviously different than humans, but if something works in an animal, it’s already promising. Thanks to the perseverence of researchers like Eng, we got one of the most exciting drugs in modern history.

The success of exenatide helped launch a wave of newer drugs built on the same basic idea. Over time, those medicines moved far beyond diabetes care and reshaped the treatment of obesity as well.

The path from desert venom to pharmacy shelves was long, expensive, and far from obvious. Even so, it changed modern medicine. What began with an obscure lizard and a difficult research question ended by opening one of the most important new chapters in metabolic treatment.